257 related articles for article (PubMed ID: 34040611)
1. Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2 + 1 Common Light Chain Antibody Architecture.
Bogen JP; Carrara SC; Fiebig D; Grzeschik J; Hock B; Kolmar H
Front Immunol; 2021; 12():669496. PubMed ID: 34040611
[TBL] [Abstract][Full Text] [Related]
2. Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody.
Harwardt J; Carrara SC; Bogen JP; Schoenfeld K; Grzeschik J; Hock B; Kolmar H
Front Immunol; 2023; 14():1170042. PubMed ID: 37081888
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors.
Wingert S; Reusch U; Knackmuss S; Kluge M; Damrat M; Pahl J; Schniegler-Mattox U; Mueller T; Fucek I; Ellwanger K; Tesar M; Haneke T; Koch J; Treder M; Fischer W; Rajkovic E
MAbs; 2021; 13(1):1950264. PubMed ID: 34325617
[TBL] [Abstract][Full Text] [Related]
4. Expeditious Generation of Biparatopic Common Light Chain Antibodies
Bogen JP; Carrara SC; Fiebig D; Grzeschik J; Hock B; Kolmar H
Front Immunol; 2020; 11():606878. PubMed ID: 33424853
[TBL] [Abstract][Full Text] [Related]
5. Grabbing the Bull by Both Horns: Bovine Ultralong CDR-H3 Paratopes Enable Engineering of 'Almost Natural' Common Light Chain Bispecific Antibodies Suitable For Effector Cell Redirection.
Klewinghaus D; Pekar L; Arras P; Krah S; Valldorf B; Kolmar H; Zielonka S
Front Immunol; 2021; 12():801368. PubMed ID: 35087526
[TBL] [Abstract][Full Text] [Related]
6. Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells.
Gantke T; Weichel M; Herbrecht C; Reusch U; Ellwanger K; Fucek I; Eser M; Müller T; Griep R; Molkenthin V; Zhukovsky EA; Treder M
Protein Eng Des Sel; 2017 Sep; 30(9):673-684. PubMed ID: 28981915
[TBL] [Abstract][Full Text] [Related]
7. Potent Apoptosis Induction by a Novel Trispecific B7-H3xCD16xTIGIT 2+1 Common Light Chain Natural Killer Cell Engager.
Ulitzka M; Harwardt J; Lipinski B; Tran H; Hock B; Kolmar H
Molecules; 2024 Mar; 29(5):. PubMed ID: 38474651
[TBL] [Abstract][Full Text] [Related]
8. Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform.
Gjetting T; Gad M; Fröhlich C; Lindsted T; Melander MC; Bhatia VK; Grandal MM; Dietrich N; Uhlenbrock F; Galler GR; Strandh M; Lantto J; Bouquin T; Horak ID; Kragh M; Pedersen MW; Koefoed K
MAbs; 2019; 11(4):666-680. PubMed ID: 31046547
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
10. Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity.
Ellwanger K; Reusch U; Fucek I; Wingert S; Ross T; Müller T; Schniegler-Mattox U; Haneke T; Rajkovic E; Koch J; Treder M; Tesar M
MAbs; 2019 Jul; 11(5):899-918. PubMed ID: 31172847
[TBL] [Abstract][Full Text] [Related]
11. Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy.
Nikkhoi SK; Li G; Eleya S; Yang G; Vandavasi VG; Hatefi A
Front Immunol; 2022; 13():1039969. PubMed ID: 36685519
[TBL] [Abstract][Full Text] [Related]
12. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
Tapia-Galisteo A; Álvarez-Vallina L; Sanz L
J Hematol Oncol; 2023 Jul; 16(1):83. PubMed ID: 37501154
[TBL] [Abstract][Full Text] [Related]
13. CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells.
Pahl JHW; Koch J; Götz JJ; Arnold A; Reusch U; Gantke T; Rajkovic E; Treder M; Cerwenka A
Cancer Immunol Res; 2018 May; 6(5):517-527. PubMed ID: 29514797
[TBL] [Abstract][Full Text] [Related]
14. A Generic Strategy to Generate Bifunctional Two-in-One Antibodies by Chicken Immunization.
Harwardt J; Bogen JP; Carrara SC; Ulitzka M; Grzeschik J; Hock B; Kolmar H
Front Immunol; 2022; 13():888838. PubMed ID: 35479092
[TBL] [Abstract][Full Text] [Related]
15. The Targeting Effect of Cetuximab Combined with PD-L1 Blockade against EGFR-Expressing Tumors in a Tailored CD16-CAR T-Cell Reporter System.
Li Y; Gao Q; Liu H; Lin S; Chen H; Ding R; Gu Y; Chao CC; Dong X
Cancer Invest; 2021 Apr; 39(4):285-296. PubMed ID: 33646061
[TBL] [Abstract][Full Text] [Related]
16. Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.
Pekar L; Klausz K; Busch M; Valldorf B; Kolmar H; Wesch D; Oberg HH; Krohn S; Boje AS; Gehlert CL; Toleikis L; Krah S; Gupta T; Rabinovich B; Zielonka S; Peipp M
J Immunol; 2021 Jan; 206(1):225-236. PubMed ID: 33268483
[TBL] [Abstract][Full Text] [Related]
17. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells.
Reusch U; Burkhardt C; Fucek I; Le Gall F; Le Gall M; Hoffmann K; Knackmuss SH; Kiprijanov S; Little M; Zhukovsky EA
MAbs; 2014; 6(3):728-39. PubMed ID: 24670809
[TBL] [Abstract][Full Text] [Related]
18. Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies.
Zhao Y; Li Y; Wu X; Li L; Liu J; Wang Y; Liu Y; Li Q; Wang Z
Cancer Biol Ther; 2020; 21(1):72-80. PubMed ID: 31564196
[TBL] [Abstract][Full Text] [Related]
19. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
[TBL] [Abstract][Full Text] [Related]
20. A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade.
Geuijen C; Tacken P; Wang LC; Klooster R; van Loo PF; Zhou J; Mondal A; Liu YB; Kramer A; Condamine T; Volgina A; Hendriks LJA; van der Maaden H; Rovers E; Engels S; Fransen F; den Blanken-Smit R; Zondag-van der Zande V; Basmeleh A; Bartelink W; Kulkarni A; Marissen W; Huang CY; Hall L; Harvey S; Kim S; Martinez M; O'Brien S; Moon E; Albelda S; Kanellopoulou C; Stewart S; Nastri H; Bakker ABH; Scherle P; Logtenberg T; Hollis G; de Kruif J; Huber R; Mayes PA; Throsby M
Nat Commun; 2021 Jul; 12(1):4445. PubMed ID: 34290245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
